NALMEFENE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nalmefene, and what generic alternatives are available?
Nalmefene is a drug marketed by Chengdu Shuode and Purdue Pharma Lp and is included in two NDAs.
The generic ingredient in NALMEFENE is nalmefene hydrochloride. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the nalmefene hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nalmefene
A generic version of NALMEFENE was approved as nalmefene hydrochloride by PURDUE PHARMA LP on February 8th, 2022.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for NALMEFENE?
- What are the global sales for NALMEFENE?
- What is Average Wholesale Price for NALMEFENE?
Summary for NALMEFENE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Drug Prices: | Drug price information for NALMEFENE |
| DailyMed Link: | NALMEFENE at DailyMed |
US Patents and Regulatory Information for NALMEFENE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chengdu Shuode | NALMEFENE HYDROCHLORIDE | nalmefene hydrochloride | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 216007-001 | Nov 15, 2023 | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Chengdu Shuode | NALMEFENE HYDROCHLORIDE | nalmefene hydrochloride | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 216007-002 | Nov 15, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Purdue Pharma Lp | NALMEFENE HYDROCHLORIDE | nalmefene hydrochloride | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 212955-001 | Feb 8, 2022 | AP | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
